[Federal Register Volume 68, Number 52 (Tuesday, March 18, 2003)]
[Notices]
[Pages 12912-12913]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-6369]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


National Mammography Quality Assurance Advisory Committee; Notice 
of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: National Mammography Quality Assurance Advisory 
Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on April 28, 2003, from 9 
a.m. to 6 p.m.
    Location: Holiday Inn, Walker/Whetstone Rooms, Two Montgomery 
Village Ave., Gaithersburg, MD.
    Contact Person: Charles Finder, Center for Devices and Radiological 
Health (HFZ-240), Food and Drug Administration, 1350 Piccard Dr., 
Rockville, MD 20850, 301-594-3332, or FDA Advisory Committee 
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC 
area), code 12397. Please call the Information Line for up-to-date 
information on this meeting.
    Agenda: The committee will receive information on the 
reauthorization of the Mammography Quality Standards Act (MQSA) and 
will discuss the potential impact of reauthorization on the current 
regulations particularly as it relates to personnel competency. The 
committee will also discuss mechanisms to recruit and retain 
mammography personnel as well as the latest draft and final MQSA 
compliance guidance changes. The committee will receive updates on 
approved alternative standards, the status of accreditation and 
certification of full field digital mammography, current inspection 
follow-up actions, and an overview of inspection observations. The MQSA 
compliance guidance documents, which are in a question and answer 
format, are available to the public on the Internet at http://www.fda.gov/cdrh/mammography. This guidance is being updated 
continually in response to questions that FDA receives from the public.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person by March 31, 
2003. Oral presentations from the public will be scheduled between 
approximately 9:30 a.m. and 10:30 a.m. on April 28, 2003. Time allotted 
for each presentation may be limited. Those desiring to make formal 
oral presentations should notify the contact person before March 31, 
2003, and submit a brief statement of the general nature of the 
evidence or arguments they wish to present, the names and addresses of 
proposed participants, and an indication of the approximate time 
requested to make their presentation.
    Persons attending FDA's advisory committee meetings are advised 
that the agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact Shirley Meeks, 
Conference Management Staff, at 301-594-1283, ext. 105, at least 7 days 
in advance of the meeting.

[[Page 12913]]

    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: March 10, 2003.
Linda Arey Skladany,
Associate Commissioner for External Relations.
[FR Doc. 03-6369 Filed 3-17-03; 8:45 am]
BILLING CODE 4160-01-S